Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors

Stratigou, Theodora; Antonakos, Georgios; Marinou, Ioanna; Vogiatzakis, E.; Christodoulatos, Gerasimos Socrates; Karampela, Ιrene; Papavassiliou, Athanasios G.

doi:10.1007/s12020-018-1550-3

Cited by 44 publications

(47 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Stratigou and cols. suggested that irisin might represent an adipo-myokine counterbalancing the deterioration of lipid metabolism and insulin sensitivity in SCH as well as reflecting a protective compensatory mechanism against oxidative muscle and thyroid cell stress (15). In our study irisin levels in subclinical hypothyroid patients were similar to healthy controls.…”

Section: Adipokines In Subclinical Hypothyroidismsupporting

confidence: 71%

“…Irisin was previously studied in patients with SCH (14,15), but only Stratigou and cols. evaluated serum irisin levels after being euthyroid with levothyroxine treatment (15). Apelin was studied in patients with SCH (10,13), however it was also not evaluated after becoming euthyroid.…”

Section: Adipokines In Subclinical Hypothyroidismmentioning

confidence: 99%

“…found decreased irisin levels in long-standing hypothyroidism and suggested that it might result from muscle damage due to prolonged myopathy and leakage of irisin from damaged muscle cells (7). Only two studies evaluated circulating irisin levels in SCH: Although irisin levels were similar between euthyroid and subclinical hypothyroid patients in one study (14), it was reported to be increased in the other study (15). Stratigou and cols.…”

Section: Adipokines In Subclinical Hypothyroidismmentioning

confidence: 99%

See 2 more Smart Citations

Serum irisin and apelin levels and markers of atherosclerosis in patients with subclinical hypothyroidism

Yaşar¹,

Demirpençe²,

Çolak³

et al. 2019

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

Objective: In this study, we aimed to evaluate serum irisin and apelin levels in patients with subclinical hypothyroidism (SCH) when they were subclinical hypothyroid and become euthyroid after levothyroxine therapy and association of these adipokines with markers of atherosclerosis such as serum homocysteine levels and carotid intima-media thickness (IMT). Subjects and methods: The study included 160 patients with newly diagnosed subclinical hypothyroidism due to Hashimoto's thyroiditis and 86 euthyroid healty subjects. Serum glucose and lipid profile, insulin, HOMA, TSH, free T3, free T4, anti-thyroperoxidase and anti-thyroglobulin antibodies, homocysteine, apelin and irisin levels were measured in all study subjects. Thyroid and carotid ultrasound examinations were performed. The subclinical hypothyroid group was reevaluated after 12-weeks of levothyroxine therapy when they became euthyroid. Results: Clinical characteristics of the patient and control group were similar. Glucose, insulin and HOMA levels, lipid parameters and free T3 were similar between the two groups.. Serum homocystein was higher and apelin was lower in patients with SCH, but irisin levels were similar between the two groups. While thyroid volume was lower, carotid IMT was significantly greater in patients with SCH (pCarotidIMT:0,01). After 12-weeks of levothyroxine therapy, all the studied parameters remained unchanged except, serum freeT4, TSH, homocystein and apelin. While homocystein decreased (p: 0,001), apelin increased significantly (p = 0,049). In multivariate analysis, low apelin levels significantly contributed to carotid IMT (p = 0,041). Conclusions: Apelin-APJ system may play a role in vascular and cardiac dysfunction in patients with SCH and treatment of this condition may improve the risk of cardiovascular disease.

show abstract

Section: Adipokines In Subclinical Hypothyroidismsupporting

confidence: 71%

Section: Adipokines In Subclinical Hypothyroidismmentioning

confidence: 99%

Section: Adipokines In Subclinical Hypothyroidismmentioning

confidence: 99%

See 1 more Smart Citation

Serum irisin and apelin levels and markers of atherosclerosis in patients with subclinical hypothyroidism

Yaşar¹,

Demirpençe²,

Çolak³

et al. 2019

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

show abstract

“…Full-text evaluation excluded 158 articles. Thus, 29 articles were included in the final meta-analysis ( 23 – 27 , 40 – 63 ). Among them, 10 studies were RCTs including 1,637 participants ( 40 – 49 ) and the other 19 studies were prospective follow-up studies including 571 participants ( 23 – 27 , 50 – 63 ).…”

Section: Resultsmentioning

confidence: 99%

“…Some studies suggested that LT4 therapy could offer benefits for SCH patients through decreasing TSH level, such as the lipid-lowering effect ( 21 , 22 ). Findings from several studies revealed that LT4 therapy reduced blood pressure in SCH patients ( 23 – 25 ), but other studies did not support it ( 26 , 27 ). Therefore, there is still no consensus regarding the effect of LT4 therapy on blood pressure in SCH patients.…”

Section: Introductionmentioning

confidence: 99%

Effect of Levothyroxine on Blood Pressure in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis

Zhang

et al. 2018

Front. Endocrinol.

View full text Add to dashboard Cite

Background: Patients with subclinical hypothyroidism (SCH) have elevated blood pressure, but the effect of levothyroxine (LT4) therapy on blood pressure among those patients is still unclear. This study aimed to assess whether LT4 therapy could reduce blood pressure in SCH patients through a systematic review and meta-analysis.Methods: PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science were searched. Randomized controlled trials (RCTs) assessing the effect of LT4 therapy on blood pressure or prospective follow-up studies comparing the blood pressure level before and after LT4 treatment were included, and the mean difference of systolic blood pressure (SBP) or diastolic blood pressure (DBP) was pooled using random-effect meta-analysis.Results: Twenty-nine studies including 10 RCTs and 19 prospective follow-up studies were eligible for the analysis. Meta-analysis of 10 RCTs suggested that LT4 therapy could significantly reduce SBP in SCH patients by 2.48 mmHg (95% CI −4.63 to −0.33, P = 0.024). No heterogeneity was observed among these 10 RCTs (I2 = 0%). Meta-analysis of the 19 prospective follow-up studies found that LT4 therapy significantly decreased SBP and DBP by 4.80 mmHg (95%CI −6.50 to −3.09, P < 0.001) and 2.74 mmHg (95%CI −4.06 to −1.43, P < 0.001), respectively.Conclusion: The findings suggest that LT4 replacement therapy can reduce blood pressure in SCH patients, which needs to be validated in more clinical trials with larger samples.

show abstract

Thyroid and Cardiovascular Risk

Elzen¹,

Mooijaart²,

Ballieux³

et al. 2020

Thyroid and Heart

View full text Add to dashboard Cite

Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors

Cited by 44 publications

References 42 publications

Serum irisin and apelin levels and markers of atherosclerosis in patients with subclinical hypothyroidism

Serum irisin and apelin levels and markers of atherosclerosis in patients with subclinical hypothyroidism

Effect of Levothyroxine on Blood Pressure in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis

Thyroid and Cardiovascular Risk

Contact Info

Product

Resources

About